IDEAYA BIOSCIENCE DL-01
IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methion… Read more
Market Cap & Net Worth: IDEAYA BIOSCIENCE DL-01 (30J)
IDEAYA BIOSCIENCE DL-01 (F:30J) has a market capitalization of $2.72 Billion (€2.65 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #4565 globally and #450 in its home market, demonstrating a 7.09% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IDEAYA BIOSCIENCE DL-01's stock price €30.20 by its total outstanding shares 87666408 (87.67 Million).
IDEAYA BIOSCIENCE DL-01 Market Cap History: 2019 to 2026
IDEAYA BIOSCIENCE DL-01's market capitalization history from 2019 to 2026. Data shows growth from $674.90 Million to $2.72 Billion (27.36% CAGR).
IDEAYA BIOSCIENCE DL-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IDEAYA BIOSCIENCE DL-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 30J by Market Capitalization
Companies near IDEAYA BIOSCIENCE DL-01 in the global market cap rankings as of March 18, 2026.
Key companies related to IDEAYA BIOSCIENCE DL-01 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
IDEAYA BIOSCIENCE DL-01 Historical Marketcap From 2019 to 2026
Between 2019 and today, IDEAYA BIOSCIENCE DL-01's market cap moved from $674.90 Million to $ 2.72 Billion, with a yearly change of 27.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.72 Billion | +2.72% |
| 2025 | €2.65 Billion | +19.51% |
| 2024 | €2.21 Billion | -22.64% |
| 2023 | €2.86 Billion | +89.29% |
| 2022 | €1.51 Billion | -18.45% |
| 2021 | €1.85 Billion | +103.96% |
| 2020 | €908.87 Million | +34.67% |
| 2019 | €674.90 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of IDEAYA BIOSCIENCE DL-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.72 Billion USD |
| MoneyControl | $2.72 Billion USD |
| MarketWatch | $2.72 Billion USD |
| marketcap.company | $2.72 Billion USD |
| Reuters | $2.72 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.